NASDAQ:EDGE Edge Therapeutics (EDGE) Stock Price, News & Analysis → The Military's $700M 'AI Software Bullet' (From Behind the Markets) (Ad) Free EDGE Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.66▼$2.8150-Day Range$0.50▼$6.7152-Week Range$0.28▼$17.38Volume282,467 shsAverage Volume373,201 shsMarket Capitalization$84.13 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsHeadlinesTrendsStock AnalysisCompetitorsHeadlinesTrends Get Edge Therapeutics alerts: Email Address Ad Prosper Trading AcademyBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and finds hot stocks that you probably have never even heard of… …it recommends the best potential strategy to use on the names it finds (with historical data to prove it)Click Here To Read More About This Game Changing AI Tool About Edge Therapeutics Stock (NASDAQ:EDGE)PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ.Read More Ad Prosper Trading AcademyBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and finds hot stocks that you probably have never even heard of… …it recommends the best potential strategy to use on the names it finds (with historical data to prove it)Click Here To Read More About This Game Changing AI Tool EDGE Stock News HeadlinesMay 29, 2024 | markets.businessinsider.comiBIO’s Strategic Advancements and Technological Edge Justify Buy RatingMay 29, 2024 | finance.yahoo.comEpilepsy Therapeutics Market Poised for Growth; Innovations and Advances to Fuel Expansion Through 2034June 18, 2024 | Behind the Markets (Ad)Will this AI Micro-Cap be Bigger than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout AI stock. But right now... There's only ONE AI stock you should be watching.May 28, 2024 | finance.yahoo.comLucy Therapeutics Secures New Funding to Advance New Alzheimer’s and Parkinson’s TreatmentsMay 28, 2024 | tmcnet.comLucy Therapeutics Secures New Funding to Advance New Alzheimer's and Parkinson's TreatmentsMay 23, 2024 | finance.yahoo.comDegron Therapeutics Announces Multi-Target Collaboration and Exclusive License Agreement with Takeda to Discover Molecular Glue DegradersMay 21, 2024 | finance.yahoo.comIntrommune Therapeutics Presents Oral Mucosal Immunotherapy Updates at Leading Industry EventsMay 21, 2024 | finance.yahoo.comRactigen Therapeutics Secures FDA Fast Track Designation for RAG-01, a First-in-Class saRNA TherapyJune 18, 2024 | Behind the Markets (Ad)Will this AI Micro-Cap be Bigger than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout AI stock. But right now... There's only ONE AI stock you should be watching.May 20, 2024 | markets.businessinsider.comBuy Rating Affirmed: Autolus Therapeutics’ Strategic Position and Upcoming Catalysts Promise Upside PotentialMay 17, 2024 | finance.yahoo.comPsychedelicNewsWire Named Official Media Sponsor of the 4th Annual Psychedelic Therapeutics and Drug Development ConferenceMay 16, 2024 | markets.businessinsider.com4th Annual Psychedelic Therapeutics and Drug Development Conference Scheduled for May 23-24 in Boston, MAMay 14, 2024 | finance.yahoo.comATED Therapeutics Ltd. Finalist in Health Products Category of Fast Company’s 2024 World Changing Ideas AwardsMay 14, 2024 | markets.businessinsider.comTavros Therapeutics Achieves Two Milestone Payments in its Collaboration with Vividion TherapeuticsMay 12, 2024 | seekingalpha.comWhat Makes Viking Therapeutics An Attractive Takeover Target Or Big Pharma PartnerMay 12, 2024 | seekingalpha.comWhat Makes Viking Therapeutics An Attractive Takeover Target Or Big Pharma PartnerMay 10, 2024 | markets.businessinsider.comKey Takeaways From Relay Therapeutics Analyst RatingsMay 9, 2024 | finance.yahoo.comLisata Therapeutics Net Loss Declines From a Year EarlierMay 9, 2024 | finance.yahoo.comCB Therapeutics Introduces Sustainable Retinol ProductionMay 7, 2024 | finance.yahoo.comTopas Therapeutics Appoints Hugo Fry as CEOMay 7, 2024 | markets.businessinsider.comAtopia Therapeutics, Formerly HpVac, Announces Appointment of Dr. Gregoire Chevalier as CEO and Business UpdateMay 3, 2024 | markets.businessinsider.comOptimistic Buy Rating for Dyne Therapeutics Backed by Promising DYNE-101 Drug Efficacy DataMay 2, 2024 | uk.finance.yahoo.comCorcept Therapeutics Inc (CORT) Q1 2024 Earnings Call Transcript Highlights: Strong Growth Amid ...May 2, 2024 | finanznachrichten.de500Newswire, LLC: CB Therapeutics Unveils Revolutionary Breakthroughs in Crafting Pharmaceutical-Grade Cannabinoids and AnaloguesMay 2, 2024 | finance.yahoo.comCB Therapeutics Unveils Revolutionary Breakthroughs in Crafting Pharmaceutical-Grade Cannabinoids and AnaloguesMay 2, 2024 | finance.yahoo.comKelonia Therapeutics to Participate in Upcoming Scientific ConferencesApril 30, 2024 | finance.yahoo.comAsimov Achieves 10x Improvement in Lentiviral Production, Launches New Stable Cell Line Development ServiceSee More Headlines Receive EDGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edge Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/01/2018Today6/18/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:EDGE CUSIPN/A CIK1472091 Webwww.edgetherapeutics.com Phone(800) 208-3343FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,860,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-81.29% Return on Assets-56.92% Debt Debt-to-Equity RatioN/A Current Ratio5.59 Quick Ratio5.59 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.95 per share Price / Book2.93Miscellaneous Outstanding Shares31,510,000Free FloatN/AMarket Cap$87.76 million OptionableNot Optionable Beta3.65 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesFrank K. Bedu-AddoPresident, Chief Executive Officer & DirectorMichael P. KingChief Financial OfficerLauren WoodChief Medical OfficerGregory L. ConnChief Scientific OfficerJanetta TrochimiukControllerKey CompetitorsXeris BiopharmaNASDAQ:XERSEmergent BioSolutionsNYSE:EBSAtea PharmaceuticalsNASDAQ:AVIRAlto NeuroscienceNYSE:ANROSilverback TherapeuticsNASDAQ:SBTXView All Competitors EDGE Stock Analysis - Frequently Asked Questions How were Edge Therapeutics' earnings last quarter? Edge Therapeutics, Inc. (NASDAQ:EDGE) announced its quarterly earnings data on Thursday, November, 1st. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.16. What other stocks do shareholders of Edge Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Edge Therapeutics investors own include ContraFect (CFRX), Amicus Therapeutics (FOLD), McEwen Mining (MUX), Cerecor (CERC), Synergy Pharmaceuticals (SGYP), Arena Pharmaceuticals (ARNA), BioLineRx (BLRX), Corbus Pharmaceuticals (CRBP), CRISPR Therapeutics (CRSP) and Fate Therapeutics (FATE). This page (NASDAQ:EDGE) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredAvoid These AI Stocks Like the Plague...Artificial intelligence stocks are carrying the market. One of them, Nvidia, recently became the seventh co...Weiss Ratings | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edge Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edge Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.